Allstate Corp Makes New Investment in Kenvue Inc. $KVUE

Allstate Corp bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 70,956 shares of the company’s stock, valued at approximately $1,152,000.

Several other hedge funds have also modified their holdings of the stock. UMB Bank n.a. boosted its position in Kenvue by 22.3% in the 2nd quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after buying an additional 521 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Kenvue by 80.7% during the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after acquiring an additional 16,164 shares during the period. GAMMA Investing LLC lifted its stake in shares of Kenvue by 23.9% during the second quarter. GAMMA Investing LLC now owns 30,703 shares of the company’s stock valued at $643,000 after acquiring an additional 5,925 shares during the period. CHICAGO TRUST Co NA acquired a new stake in Kenvue in the second quarter worth about $452,000. Finally, Fifth Third Bancorp increased its position in Kenvue by 0.9% in the second quarter. Fifth Third Bancorp now owns 238,928 shares of the company’s stock worth $5,001,000 after purchasing an additional 2,053 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

Shares of KVUE opened at $17.38 on Thursday. The stock has a 50 day simple moving average of $17.01 and a 200 day simple moving average of $18.19. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The firm has a market capitalization of $33.29 billion, a PE ratio of 23.17 and a beta of 0.60.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date of this dividend was Wednesday, November 12th. Kenvue’s payout ratio is currently 110.67%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Johnson Rice restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Edward Jones lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Evercore ISI set a $18.00 price objective on shares of Kenvue in a research note on Tuesday, October 28th. The Goldman Sachs Group lowered their target price on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, October 2nd. Finally, Jefferies Financial Group cut their price target on Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $20.23.

Insiders Place Their Bets

In other news, Director Jeffrey C. Smith bought 3,200,000 shares of the stock in a transaction on Friday, December 12th. The stock was purchased at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the acquisition, the director owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 1.68% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.